| Combined treatment with captopril, hydrochlorothiazide and pravastatin in dyslipidemic hypertensive patients. | |
| | |
MedLine Citation:
|
PMID: 8746603 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: Hypertension and hypercholesterolemia frequently coexist, necessitating concurrent treatments for both disorders. The present study aimed at evaluating the efficacy, the safety, and the toleration of captopril, an ACE inhibitor, hydrochlorothiazide, a diuretic, and pravastatin, a HMG-CoA reductase inhibitor co-administered in hypertensive patients in general practice. DESIGN: The patients were followed for 16 weeks and asked to comply with a lipid lowering diet for the whole period. Captopril, 50 mg/once daily, was administered alone for the first 4 weeks. Hydrochlorothiazide, 25 mg/day, was added after 4 weeks if required. Pravastatin treatment (20 mg/day) was started at the 8th week of the study and its dose was doubled 4 weeks later if needed. PATIENTS: A total of 603 patients with hypertension (diastolic blood pressure > or = 95 mmHg) and dyslipidemia (total cholesterol > 6.5 mmol/l) were included. SETTING: The study was performed in general practice by 230 physicians. MAIN OUTCOME MEASURE: Determination of blood pressure, circulating levels of total cholesterol, HDL-cholesterol and triglycerides, and blood chemistry for safety monitoring. RESULTS: At the end of the trial 75.1% of patients had their diastolic blood pressure < or = 90 mmHg and 43.5% a total cholesterol level < 6.5 mmol/l. The overall incidence of adverse events was 21.7%, leading to withdrawal in 10.9% of the total number of patients. The combined treatments had no deleterious effect on safety variables. CONCLUSIONS: Captopril, hydrochlorothiazide and pravastatin are effective and well tolerated medications to treat dyslipidemic hypertensive patients. |
| | |
Authors:
|
B Waeber; P Greminger; W Riesen; R Darioli; D Simeon-Dubach; R Wunderlin |
Related Documents
:
|
11693763 - Effect of the angiotensin-converting enzyme inhibitor imidapril on reactive hyperemia i... 11881103 - Angiotensin ii receptor blockers and cardiovascular outcomes: the evidence now and in t... 17351163 - Wine, diet, and arterial hypertension. |
Publication Detail:
|
Type: Clinical Trial; Journal Article |
Journal Detail:
|
Title: Blood pressure Volume: 4 ISSN: 0803-7051 ISO Abbreviation: Blood Press. Publication Date: 1995 Nov |
Date Detail:
|
Created Date: 1996-09-18 Completed Date: 1996-09-18 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9301454 Medline TA: Blood Press Country: NORWAY |
Other Details:
|
Languages: eng Pagination: 358-62 Citation Subset: IM |
Affiliation:
|
Division d'Hypertension, CHUV, Lausanne, Switzerland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Angiotensin-Converting Enzyme Inhibitors / adverse effects, therapeutic use Anticholesteremic Agents / adverse effects, therapeutic use* Antihypertensive Agents / adverse effects, therapeutic use* Captopril / adverse effects, therapeutic use Combined Modality Therapy Diuretics Drug Therapy, Combination Enzyme Inhibitors / adverse effects, therapeutic use* Female Humans Hydrochlorothiazide / adverse effects, therapeutic use Hydroxymethylglutaryl-CoA Reductase Inhibitors Hyperlipidemias / complications, diet therapy, drug therapy* Hypertension / complications, diet therapy, drug therapy* Male Middle Aged Pravastatin / therapeutic use Prospective Studies Sodium Chloride Symporter Inhibitors / adverse effects, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin-Converting Enzyme Inhibitors; 0/Anticholesteremic Agents; 0/Antihypertensive Agents; 0/Diuretics; 0/Enzyme Inhibitors; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Sodium Chloride Symporter Inhibitors; 58-93-5/Hydrochlorothiazide; 62571-86-2/Captopril; 81093-37-0/Pravastatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Trough-to-peak versus surface ratio in the assessment of antihypertensive agents. APTH Investigators...
Next Document: Effects of cilazapril on renal haemodynamics and function in hypertensive patients: a randomised con...